Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(2)
Other(3)

Detailed Status

unknown3
Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

recruiting117%
completed233%
unknown350%

Recent Activity

1 active trials
Showing 5 of 6
unknown

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

NCT04489433
completed

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

NCT03944356
completedphase_1

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

NCT02872259
unknown

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

NCT04544202
recruitingphase_2

The Drug Rediscovery Protocol (DRUP Trial)

NCT02925234
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04489433

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Unknown
NCT03944356

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Completed
NCT02872259Phase 1

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Completed
NCT04544202

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Unknown
NCT02925234Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting
NCT04554680Phase 2

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6